Advertisement
Australia markets close in 3 hours 53 minutes
  • ALL ORDS

    7,969.80
    -32.70 (-0.41%)
     
  • ASX 200

    7,719.40
    -30.30 (-0.39%)
     
  • AUD/USD

    0.6635
    -0.0002 (-0.03%)
     
  • OIL

    78.20
    -0.42 (-0.53%)
     
  • GOLD

    2,321.60
    +3.60 (+0.16%)
     
  • Bitcoin AUD

    100,590.73
    -1,759.62 (-1.72%)
     
  • CMC Crypto 200

    1,419.58
    +6.63 (+0.47%)
     
  • AUD/EUR

    0.6175
    +0.0002 (+0.04%)
     
  • AUD/NZD

    1.0778
    +0.0026 (+0.24%)
     
  • NZX 50

    11,873.43
    +0.79 (+0.01%)
     
  • NASDAQ

    19,576.92
    +111.74 (+0.57%)
     
  • FTSE

    8,163.67
    -51.81 (-0.63%)
     
  • Dow Jones

    38,647.10
    -65.11 (-0.17%)
     
  • DAX

    18,265.68
    -365.18 (-1.96%)
     
  • Hang Seng

    18,065.16
    -47.47 (-0.26%)
     
  • NIKKEI 225

    38,716.84
    -3.63 (-0.01%)
     

Why Biohaven Stock Caught Fire This Week

Why Biohaven Stock Caught Fire This Week

Shares of the clinical-stage biopharma Biohaven (NYSE: BHVN) rocketed higher by 33.5% over the first four days of trading this week, according to data provided by S&P Global Market Intelligence. The big gain was sparked by the company's research and development day presentation held on Wednesday. Highlights from Biohaven's presentation include the unexpected Food and Drug Administration (FDA) regulatory filing for the experimental spinocerebellar ataxia type 3 drug troriluzole, status updates on its closely watched epilepsy program, and a clinical strategy overview for its newly acquired neuroinflammatory asset BHV-8000.